The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans

• Published in: Clinical and translational science 2019-05, Vol.12 (3), p.209-217
• Main Authors: Friedman, Paula N., Shaazuddin, Mohammed, Gong, Li, Grossman, Robert L., Harralson, Arthur F., Klein, Teri E., Lee, Norman H., Miller, Doriane C., Nutescu, Edith A., O'Brien, Travis J., O'Donnell, Peter H., O'Leary, Kevin J., Tuck, Matthew, Meltzer, David O., Perera, Minoli A.
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 1752-8054; 1752-8062
• DOI: 10.1111/cts.12608

The majority of pharmacogenomic (PGx) studies have been conducted on European ancestry populations, thereby excluding minority populations and impeding the discovery and translation of African American–specific genetic variation into precision medicine. Without accounting for variants found in African Americans, clinical recommendations based solely on genetic biomarkers found in European populations could result in misclassification of drug response in African American patients. To address these challenges, we formed the Transdisciplinary Collaborative Center (TCC), African American Cardiovascular Pharmacogenetic Consortium (ACCOuNT), to discover novel genetic variants in African Americans related to clinically actionable cardiovascular phenotypes and to incorporate African American–specific sequence variations into clinical recommendations at the point of care. The TCC consists of two research projects focused on discovery and translation of genetic findings and four cores that support the projects. In addition, the largest repository of PGx information on African Americans is being established as well as lasting infrastructure that can be utilized to spur continued research in this understudied population.